Janux Therapeutics, Inc. JANX
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Janux Therapeutics, Inc. (JANX) is a healthcare company listed in the US with a market value of about $696M. In the twelve months to September 30, 2026 it had revenue of $23M and net income of -$100M, a net margin of -428.7%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -12%.
About Janux Therapeutics
Janux Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $4M in 2021 to $10M in 2025, growth of about 28.8% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 49% over three years (dilution for shareholders). It spends 1259% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $23M | $10M | $11M | $8M | $9M | $4M | $0 |
| Net income | -$100M | -$114M | -$69M | -$58M | -$63M | -$33M | -$7M |
| Free cash flow | -$54M | -$83M | -$44M | -$52M | -$49M | -$18M | -$4M |
| EPS (diluted) | $-1.59 | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | $-0.14 |
| Net margin | -428.7% | -1136.2% | -651.6% | -721.2% | -732.2% | -898.3% | — |
| ROIC | — | -12.7% | -7.5% | -15.6% | -15.3% | -7.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $33.14, 191% above the current price; targets range from $15.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-1.57 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Janux Therapeutics pay a dividend?
Not currently.
Is Janux Therapeutics a good stock to buy?
We do not give buy or sell advice. Janux Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.